Hisamitsu Pharmaceutical Co., Inc.
HTSUFOTCHealthcare
$29.00
+$0.00(+0.00%)
Market Cap$2.0B
P/E Ratio—
52W High$32.3
52W Low$28.94
Hisamitsu Pharmaceutical Co., Inc. (HTSUF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HTSUF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-02 | 2025-02 | 2024-02 | 2023-02 | 2022-02 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $163.49B | $156.01B | $141.71B | $128.33B | $120.19B |
| Cost of Revenue | $67.10B | $64.81B | $62.73B | $55.63B | $50.13B |
| Gross Profit | $96.40B | $91.20B | $78.97B | $72.70B | $70.07B |
| Gross Margin %(computed) | 58.96% | 58.46% | 55.73% | 56.65% | 58.30% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $8.61B | $9.79B | $10.61B |
| G&A Expenses | $0.00B | $26.53B | $25.29B | $23.22B | $20.58B |
| Total Operating Expenses | $78.43B | $72.30B | $65.80B | $61.10B | $60.73B |
| Operating Income | $17.97B | $18.89B | $13.17B | $11.60B | $9.34B |
| Operating Margin %(computed) | 10.99% | 12.11% | 9.29% | 9.04% | 7.77% |
| Interest Income | $2.37B | $2.75B | $2.56B | $0.89B | $0.15B |
| Interest Expense | $0.02B | $0.02B | $0.02B | $0.01B | $0.02B |
| Income Before Tax | $23.72B | $28.69B | $19.19B | $16.11B | $12.96B |
| Income Tax Expense | $4.12B | $6.38B | $4.75B | $3.99B | $3.09B |
| Net Income | $19.22B | $21.76B | $13.97B | $11.74B | $9.66B |
| Net Margin %(computed) | 11.75% | 13.95% | 9.86% | 9.15% | 8.04% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $269.27 | $295.57 | $181.61 | $148.00 | $118.92 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.08B | 0.08B | 0.08B |
| EBITDA | $25.04B | $35.05B | $24.38B | $16.55B | $17.30B |
| EBITDA Margin %(computed) | 15.32% | 22.46% | 17.20% | 12.90% | 14.39% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · JPY · B
Explore more Hisamitsu Pharmaceutical Co., Inc. data
About Hisamitsu Pharmaceutical Co., Inc. (HTSUF) Income Statement
Hisamitsu Pharmaceutical Co., Inc. (HTSUF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, HTSUF reported revenue of $163.49B, gross profit of $96.40B (gross margin 58.96%), and net income of $19.22B — a net profit margin of 11.75%.
Frequently asked questions
HTSUF · 4 questionsHisamitsu Pharmaceutical Co., Inc. (HTSUF) reported revenue of $163.49B for 2026, up 4.8% year-over-year.
HTSUF revenueHTSUF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09